
Opinion|Videos|March 21, 2025
Navigating the Boxed Warning for the JAK Inhibitor Class
Panelists discuss how clinicians can interpret and apply the JAK inhibitor class boxed warning to make informed treatment decisions while weighing potential risks against therapeutic benefits for individual patients.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Sonelokimab Meets Primary End Point in Phase 3 Psoriatic Arthritis Trial
2
FDA Approves Labcorp's PGDx Elio Tissue Complete CDx for Advanced Melanoma
3
Probiotics in Hidradenitis Suppurativa: Biologic Rationale vs. Clinical Evidence
4
Social Media Mythbusters: At-Home Facial Gua Sha
5








